- Rating
- 2
- Confidence
- 4
- Informativeness
- 2
- Presentation
- 3
- Soundness
- 1
Read review
Paper summary
This paper presents GITIII-scale, a scaled and pretrained extension of GITIII for modeling cell state–niche associations in the tumor microenvironment. The model is trained on a pan-cancer collection of specimen-matched imaging-based spatial transcriptomics and scRNA-seq data, with spatial profiles imputed to a shared 20,000-gene vocabulary. Architecturally, it combines an interpretable additive module that decomposes receiver-cell state predictions into sender-by-gene contributions with a deeper graph transformer that produces neighborhood-level TME embeddings.
The model is evaluated on held-out cancer types and platforms. Compared with several spatial foundation models and graph-based baselines, GITIII-scale achieves better prediction of within-cell-type expression residuals from local niches. The authors further demonstrate its interpretability using a breast cancer case study, where the model recovers KDR/VEGFR2 signaling associated with endothelial proliferation.
Critical strengths
The main strength is the two-level architecture that separates interpretability from representational capacity. The first-level additive head preserves an exact sender-by-gene decomposition of the predicted receiver-cell state, while the second-level graph transformer captures higher-order neighborhood effects and produces a more expressive TME representation. This is a sensible design choice because it avoids forcing a single module to simultaneously maximize predictive flexibility and strict decomposability. Among the methodological extensions over GITIII, this is the most convincing and potentially reusable contribution.
Critical weaknesses
-
The “foundation model” and scaling claims are not convincingly supported. GITIII-scale is pretrained on only 10 specimens, and its purported OOD evaluation still trains a supervised probe on cells from each target dataset. This shows representation transfer rather than true zero-shot generalization. More fundamentally, as a scaled successor to GITIII, the paper does not clearly demonstrate that scaling enables a qualitatively new scientific capability rather than simply improving a surrogate prediction task.
-
The validation is misaligned with the paper’s claimed biological contribution. Predicting within-cell-type expression residuals is only a proxy for the real goal of CCI/TME modeling: identifying biologically meaningful sender–receiver interactions and signaling mechanisms. Yet these attributions are not systematically benchmarked against established CCC/CCI methods. Moreover, “interpretability” is overstated: exact decomposition of a model prediction does not establish correct biological attribution or causality. The 20,000-gene “full-transcriptome spatial” setting is largely imputed rather than measured, and its added biological value is unclear. Finally, the main case study only recovers the canonical VEGF–KDR endothelial proliferation axis, demonstrating consistency with textbook biology rather than novel mechanistic discovery.
Questions for authors
Clarification requests
-
What is the key capability that makes GITIII-scale a foundation model rather than a pretrained transfer model? In particular, how should the reader interpret this claim given that pretraining uses only 10 specimens and downstream evaluation relies on target-dataset supervised probes rather than zero-shot prediction?
-
What evidence supports the claim that the inferred sender-by-gene contributions are biologically interpretable, rather than simply an exact decomposition of the model prediction? How should these attributions be distinguished from associative CCI signals already modeled by other methods, including GITIII?
-
What is the biological advantage of imputing all samples to a shared 20,000-gene vocabulary? Specifically, how robust are the inferred gene-level influences and LR pathways when they involve genes that were not spatially measured, and how much of the reported gain remains when evaluation and interpretation are restricted to measured genes only?
-
Can the authors provide a more stringent test of transferability, such as leave-one-sample/patient/cancer-type/platform-out evaluation without fitting a supervised probe on the target specimen? This would materially affect whether the current OOD and foundation-model claims are convincing.
-
For the biological discovery claim, how does GITIII-scale compare with established CCC/CCI methods on the same mechanistic tasks? In particular, can the authors show examples where GITIII-scale identifies a biologically supported interaction or pathway that is missed by existing methods, rather than recovering a canonical pathway such as VEGF–KDR?
13 comments
W1 and Q1: Foundation-model definition and transferability (Part II)
(4) Is there evidence of prediction without a target-specimen probe?
Yes. Table S6 reports the direct outputs of both pretrained heads without fitting a probe or any model parameters on the target specimen. Head 1 directly predicts cell-state residuals by summing its sender-specific influences. Its within-cell-type PCC on all genes is 0.155, 0.115, and 0.204 for Xenium Breast, MERFISH CRC, and MERFISH Melanoma, respectively; on measured genes, the corresponding values are 0.141, 0.095, and 0.193.
These direct outputs should be interpreted as probe-free within-cell-type ranking performance, not as calibrated absolute-expression predictions. As explained in Section 2.3, absolute expression scales are affected by panel sensitivity and batch effects, which differ across specimens and platforms. Consequently, a single generalized prediction head may not be optimally calibrated to the scale and offset of every target dataset. We therefore report within-cell-type PCC for the direct outputs, which is invariant to positive per-gene rescaling; we do not report target-specific R² for these direct outputs because calculating R² would require fitting a scale and offset on the target specimen. The downstream probe in Table 1 provides a lightweight way to adapt the readout to the target specimen while keeping the pretrained encoder frozen.
(5) What does scaling add beyond improving the surrogate prediction task?
The demonstrated benefit of scaling is not only improved cell-state prediction. It enables one pretrained model to learn and reuse the two-level representation described above: pairwise sender–receiver interaction embeddings and a neighborhood-level TME embedding. The pairwise representation supports sender- and gene-resolved decomposition, while the neighborhood embedding captures higher-order context across multiple senders.
The quantitative results support the transfer benefit of this representation. Frozen GITIII-scale outperforms GITIII trained separately on each target specimen on the measured-gene benchmark: R² values are 0.150 versus 0.129 for Xenium Breast, 0.074 versus 0.046 for MERFISH CRC, and 0.118 versus 0.081 for MERFISH Melanoma. Under matched optimization steps, all-gene R² on Xenium Breast rises from 0.115 to 0.158 and 0.170 as the pretraining corpus grows from approximately 2.35 million to 3.04 million and 4.25 million cells. In addition, the GITIII-scale architecture does not converge when trained from scratch on an individual evaluation specimen.
We have therefore scoped the claim carefully: GITIII-scale is a pan-cancer pretrained representation-learning model that transfers pairwise interaction and neighborhood representations to unseen specimens. The primary probe-based benchmark is frozen-representation transfer, while Table S6 separately demonstrates probe-free prediction.
Changes in the manuscript:
- Introduction: Clarification of the paired-data resource and the two levels of representation learning.
- Section 2.2: Description of the pairwise sender–receiver encoder, additive head, and neighborhood-level TME embedding.
- Section 3.2–3.4: Frozen-representation and probe-free evaluation.
- Tables 1 and 2: Transfer and corpus-scaling results.
- Appendix S9: Dataset-specific GITIII comparison.
- Appendix S12: Direct and probe-based head evaluations.
- Appendix S1: Scope of the foundation-model and transferability claims.
W2a and Q5: Comparison with established CCI methods and biological discovery
W2 (critical weakness): “The validation is misaligned with the paper’s claimed biological contribution... novel mechanistic discovery.”
Q5 (author question): “For the biological discovery claim..”
Response:
We answer the comparison and biological-discovery aspects separately. We also clarify the exact task used for the quantitative benchmark.
(1) How does GITIII-scale compare with established CCC/CCI methods, and what task do the reported results measure?
We added HoloNet (Li et al., 2023) and GITIII (Xiao et al., 2026) to the quantitative benchmarking, alongside NCEM-GCN (Fischer et al., 2023) and GAT (Veličković et al., 2018). The comparison is performed on a shared cell-state prediction task: predict the receiver cell's within-cell-type expression residual from its cellular neighborhood, using the same-type masking and spatial block evaluation protocol. GITIII, HoloNet, NCEM-GCN, and GAT are trained on the training blocks of each target specimen for this task. GITIII-scale uses its frozen pan-cancer-pretrained encoder and the same 1,024-unit downstream probe on the training blocks.
The following values are from Table 1, measured genes, evaluated on the spatially held-out validation blocks. The three columns correspond to the three specific evaluation specimens: Xenium Breast, MERFISH colorectal carcinoma (CRC), and MERFISH Melanoma. Targets are the original measured-panel assay values (313, 500, and 500 genes, respectively); R² is pooled over genes, and values are mean ± standard deviation over five seeds.
| Method | Xenium Breast R² | MERFISH CRC R² | MERFISH Melanoma R² |
|---|---|---|---|
| GITIII-scale (frozen encoder + probe) | 0.150 ± 0.002 | 0.074 ± 0.004 | 0.118 ± 0.001 |
| GITIII (trained on target specimen) | 0.129 ± 0.012 | 0.046 ± 0.011 | 0.081 ± 0.001 |
| NCEM-GCN | 0.120 ± 0.004 | 0.033 ± 0.001 | 0.070 ± 0.008 |
| HoloNet | 0.096 ± 0.001 | 0.029 ± 0.004 | 0.071 ± 0.005 |
| GAT | 0.101 ± 0.004 | 0.016 ± 0.010 | 0.041 ± 0.007 |
GITIII-scale achieves the highest measured-gene R² across all three held-out specimens. These results show that its learned representations are more effective for the shared quantitative cell-state prediction task than the evaluated dataset-specific CCI models. They are not, by themselves, a direct benchmark of the causal correctness of each method's mechanistic LR rankings.
(2) Can we show an example of a biologically supported interaction that GITIII-scale identifies?
The breast cancer case study prioritizes SEMA6D→PLXNA1–KDR, rather than the canonical VEGF-A→KDR interaction implied by the original description. The selected pair is top-ranked across all five selection-stability repetitions. Its score achieves a PCC of 0.230 with measured MKI67 in spatially held-out Xenium Breast endothelial cells, compared with 0.147 for KDR expression alone and 0.104 for unweighted ligand–receptor co-expression.
The receptor complex PLXNA1–KDR has been reported to mediate Sema6D-induced endocardial cell migration during cardiac development (Toyofuku et al., 2004). This provides biological context for the candidate association, but does not establish that the same mechanism drives proliferation in breast tumor endothelium. We therefore describe it as a testable hypothesis.
(3) Can we claim that this interaction is missed by existing CCI methods?
We do not make that claim. The observational datasets do not provide ground truth for the causal correctness of inferred LR-to-target relationships, so we cannot establish that another method misses the true interaction. The added HoloNet, GITIII, NCEM-GCN, and GAT comparisons evaluate the shared cell-state prediction task, while the receptor-only and unweighted co-expression comparisons evaluate the predictive contribution of the selected LR score. These are complementary forms of evidence, not a direct causal ranking benchmark.
The revised manuscript therefore makes two distinct claims: GITIII-scale improves cell-state prediction relative to the evaluated CCI models, and its LR analysis can prioritize spatially informed candidate signaling hypotheses. It does not claim to establish causal mechanisms or to show that other methods fail to identify them.
Changes in the manuscript:
- Section 3.3 and Table 1: Quantitative comparison with HoloNet, GITIII, NCEM-GCN, and GAT.
- Appendix S7: Baseline implementation and training protocols.
- Section 3.5 and Figure 2: Revised SEMA6D→PLXNA1–KDR case study.
- Appendix S15: Held-out LR baseline comparisons.
- Appendix S1: Scope of biological interpretation and lack of causal ground truth.
## W1 and Q1: Foundation-model definition and transferability (Part I)
W1 and Q1: Foundation-model definition and transferability
Response:
We address the conceptual capability, the paired-data resource, and the two evaluation settings separately.
(1) What capability makes GITIII-scale a foundation model in this study?
GITIII-scale is a hierarchical representation-learning model designed to learn both pairwise sender–receiver interactions and the cellular neighborhood as a whole. Its representation learning operates at two corresponding levels:
Thus, GITIII-scale does not only encode individual cells or tissue domains. It learns representations of who interacts with whom, under what spatial relationship, and how the collection of pairwise interactions forms a receiver's cellular niche. The model is pretrained once on the pan-cancer corpus and then reused with frozen parameters on unseen specimens. This reusable pairwise and neighborhood-level representation is the foundation-model capability we claim.
(2) How should the reader interpret pretraining on only 10 specimens?
Specimen-matched imaging-based spatial transcriptomics (IST) and scRNA-seq data are relatively scarce because both assays must be available for the same biological specimen, a requirement also reflected in recent paired-data imputation frameworks (Haviv et al., 2025; Li et al., 2025; Yang et al., 2026). This requirement is important: IST supplies single-cell spatial positions, whereas scRNA-seq supplies transcriptome-wide information, and the matched measurements allow us to combine these complementary modalities.
Our assembled corpus contains 10 paired samples spanning four tumor contexts and two imaging platforms, comprising 4,254,069 spatial cells. We distinguish the number of independent paired samples from the number of cells: the corpus contains 10 biological samples, while the millions of cells provide substantial cell-level training data within those samples. We therefore define the scope of the foundation-model claim in terms of this multi-sample, multi-context, multi-platform paired resource, rather than claiming universal coverage of all cancer types or platforms.
(3) Does the primary benchmark demonstrate zero-shot generalization when a probe is fitted on each target specimen?
No. The primary benchmark in Table 1 demonstrates frozen-representation transfer, not zero-shot prediction. The pretrained GITIII-scale encoder is kept frozen, and a 1,024-unit downstream probe is fitted using training-block cells from each target specimen. The probe does not update the pretrained encoder. Performance is then evaluated on spatially held-out validation blocks. This tests whether the pretrained representation captures transferable cell-state–niche information that can be read out from a limited amount of target-specimen training data.